The Hippo

HOME| ADVERTISING | CONTACT US|

Valcyte for Cytomegalovirus in Children Concord NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Lafontaine Mildred H PHYS
(603) 224-6691
248 Pleasant Street
Concord, NH
 
Dr.Eric Shulman
(603) 226-6100
253 Pleasant Street
Concord, NH
Gender
M
Education
Medical School: Univ Of Ma Med Sch
Year of Graduation: 1996
Speciality
Pediatrician
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Nancy Joan Van Vranken, MD
(603) 226-6100
253 Pleasant St
Concord, NH
Specialties
Pediatrics
Gender
Female
Education
Medical School: Univ Of Mi Med Sch, Ann Arbor Mi 48109
Graduation Year: 1977

Data Provided by:
William Robert Storo, MD
(603) 226-6100
253 Pleasant St
Concord, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Univ Of Ct Sch Of Med, Farmington Ct 06032
Graduation Year: 1992

Data Provided by:
Eric Aaron Shulman, MD
(603) 226-6100
253 Pleasant St
Concord, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Univ Of Ma Med Sch, Worcester Ma 01655
Graduation Year: 1996

Data Provided by:
Freidenberg David S PHYS
(603) 224-9995
248 Pleasant Street
Concord, NH
 
Dolly R Courtemanche, MD, FAAP
248 Pleasant St Ste 1700
Concord, NH
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 1991

Data Provided by:
Thomas Moore Albushies, MD
(603) 224-1929
248 Pleasant St Ste 1700
Concord, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Dartmouth Med, Hanover Nh 03755
Graduation Year: 1999

Data Provided by:
Emley Warren E PHYS
(603) 224-2353
194 Pleasant Street
Concord, NH
 
Wilczynski Stephen W PHYS
(603) 224-9661
248 Pleasant Street
Concord, NH
 
Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu